Rapamune 1mg Tablet

Rapamune 1mg tablet is a prescription-based medication that should be taken under a doctor's guidance. The medication is used to help prevent organ rejection in kidney transplantation. Its salt composition is Sirolimus. It acts as an immunosuppressant by inhibiting the mTOR pathway and reducing T cell activation and proliferation. It belongs to the group of mTOR inhibitors (immunosuppressive agents). Regular monitoring by the healthcare professional is necessary to ensure safe and effective treatment. The patient should follow the prescribed dose exactly and report any unusual symptoms or side effects immediately.

• Help to prevent organ rejection in patients with kidney transplantation

Every medication has several side effects that may vary from person to person and should be monitored by a healthcare professional. Common ones include:

• Fatigue or weakness
• Nausea and vomiting

• Rash
• Infrequent, absent, or heavy periods
• Rapid heart rate
• High blood sugar
• Joint pain
• Acne
• Swelling of the body, including feet and hands

• Headache
• Fever, pain
• High blood pressure and cholesterol levels
• Constipation, diarrhea, stomach pain

Rapamune 1mg tablet should be taken with a whole glass of water with or without food at the same time every day. Do not self-administer as it can cause side effects. Always follow the recommended dosage and never adjust or skip doses without consultation with a healthcare professional, as this can increase the risk of organ rejection or other complications.

After transplantation, the immune system sees the new organ as foreign and tries to attack it. Rapamune 1mg tablet weakens this immune response by inhibiting the activity and growth of immune cells that cause rejection. This helps the body accept and keep the transplanted organ working well.

• Basa-Dénes, O., Angi, R., Kárpáti, B., Jordán, T., Ötvös, Z., Erdősi, N., ... & Glavinas, H. (2019). Dose escalation study to assess the pharmacokinetic parameters of a nano-amorphous oral sirolimus formulation in healthy volunteers. European Journal of Drug Metabolism and Pharmacokinetics, 44(6), 777-785. https://pubmed.ncbi.nlm.nih.gov/31089971/
• Wyeth, T. M. (2017). Pr RAPAMUNE®. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021083s059,021110s076lbl.pdf
• Tejani, A., Alexander, S., Ettenger, R., Lerner, G., Zimmerman, J., Kohaut, E., & Briscoe, D. M. (2004). Safety and pharmacokinetics of ascending single doses of sirolimus (Rapamune®, rapamycin) in pediatric patients with stable chronic renal failure undergoing dialysis 1. Pediatric transplantation, 8(2), 151-160. https://pubmed.ncbi.nlm.nih.gov/15049795/
• Tao, C., Wen, X., Zhang, Q., & Song, H. (2019). Solid sirolimus self-microemulsifying drug delivery system: development and evaluation of tablets with sustained release property. Iranian Journal of Pharmaceutical Research: IJPR, 18(4), 1648. https://pmc.ncbi.nlm.nih.gov/articles/PMC7059041/
• Business, B. (2017). 7.7. 1 mTOR Inhibitors Rapamune®(Sirolimus) and AfinitorⓇ. Translating Molecules into Medicines: Cross-Functional Integration at the Drug Discovery-Development Interface, 25, 258.